The central role of 5,10-methylenetetrahydrofolate reductase (MTHFR) and methylenetetrahydrofolate dehydrogenase (MTHFD1) in folate metabolism renders polymorphisms in genes encoding these enzymes potential modulators of therapeutic response to antifolate chemotherapeutics. The analysis of 201 children treated with methotrexate for childhood acute lymphoblastic leukemia (ALL) showed that patients with either the MTHFR T677A1298 haplotype or MTHFD1 A1958 variant had a lower probability of event-free survival (EFS) in univariate analysis (hazard ratio (HR) ¼ 2.2, 95% confidence interval (CI), 1.0-4.7 and 2.8, 95% CI, 1.1-7.3, respectively). Multivariate analysis supported only the role of the MTHFR variant (HR ¼ 2.2, 95% CI, 0.9-5.6). However, the association of both genes with ALL outcome appears to be more obvious in the presence of another event-predisposing variant belonging to the same path of drug action. The combined effect of a thymidylate synthase (TS) triple repeat associated with increased TS levels, with either the MTHFR T677A1298 haplotype or MTHFD1 A1958 allele, resulted in a highly significant reduction of EFS (multivariate HR ¼ 9.0, 95% CI, 1.9-42.8 and 8.9, 95% CI, 1.8-44.6, respectively). These results reveal the role of gene-gene interactions within a folate pathway, and how they can correlate with relapse probabilities in ALL patients.
INTRODUCTION
The 5,10-methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-methylenetetrahydrofolate (5,10-methylene-THF) into 5-methyltetrahydrofolate (5-methyl-THF), a major circulating form of folate that provides a methyl group for homocysteine methylation.
1,2 5,10-Methylene-THF and its derivates, such as 10-formyl tetrahydrofolate (10-formyl-THF), are essential cofactors for thymidylate and de novo purine synthesis, and are provided by the action of the trifunctional enzyme, methylenetetrahydrofolate dehydrogenase/ methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase (MTHFD1). [1] [2] [3] Since MTHFR and MTHFD1 are key players in folate metabolism, the differences in their activity due to their respective gene variants could not only modify susceptibility to different diseases 2 but might also modulate therapeutic response to antifolate chemotherapeutic agents. One such agent is methotrexate (MTX), which, besides 6-mercaptopurine, is considered as a key component in the treatment of childhood acute lymphoblastic leukemia (ALL).
Two common polymorphisms, a C677 to T transition causing an alanine to valine substitution at codon 222 (Ala222Val) 4 and an A1298 to C transversion causing a glutamic acid to alanine replacement at codon 429 (Glu429Ala), 5, 6 have been described in the MTHFR gene. Both variants have an impact on enzyme function: 677T affecting the catalytic and 1298C the regulatory MTHFR domain. 4, 5 Reduced enzymatic activity has been observed in TT677 or CC1298 homozygotes, and to a lesser extent in heterozygous individuals. 4, 6, 7 The role of MTHFR variants in a number of disorders, involving disturbances in folate metabolism, such as neural tube defects (NTDs), 8 vascular disease 9, 10 and cancer susceptibility, is well documented. 11, 12 Recently, the potential role of these polymorphisms in response to MTX treatment has been addressed in several studies. [13] [14] [15] [16] Higher in vitro MTX sensitivity of a patient's lymphoblasts with the TT677 genotype has been shown. 13 Likewise, among adult acute lymphoblastic leukemia (ALL) and chronic myelogenic leukemia (CML) patients receiving MTX, higher drug toxicity was observed in TT677 homozygotes as compared to individuals with other MTHFR genotypes. 14, 15 The G to A substitution at position 1958 of the MTHFD1 gene, causing an alanine to glycine substitution at codon 653 located within the 10-formyl-THF synthetase enzyme domain, has recently been reported. 17 The role of an MTHFD1 A1958 variant in NTD susceptibility suggested the possibility of its functional impact. 18 Since MTHFR and MTHFD1 polymorphisms might affect MTX sensitivity through their impact on 5-methyl-THF and 5,10-methylene-THF levels, we assessed here the association of these polymorphisms with event-and disease-free survival (EFS and DFS), overall survival (OS), as well as with the frequency of weeks with MTX dose reduction or withdrawal in children who received this drug for the treatment of ALL. Given that MTX polyglutamates directly inhibit folate-dependent enzymes, 19, 20 along with the fact that thymidylate synthase (TS) requires for its activity 5,10-methylene-THF, 11, 21, 22 it is possible that increased levels of this cofactor, produced by altered MTHFR and/or MTHFD1 action, might facilitate thymidylate synthesis thus interfering with MTX action. This would be particularly obvious in ALL patients with increased TS levels, such as for those that are homozygous for a triple repeat (3R) of the 5 0 UTR TS polymorphism. 23 Homozygous TS 3R ALL patients have previously been shown to have an increased risk of event. 24 Therefore, we also assessed the association of MTHFR and MTHFD1 polymorphisms with ALL outcome in the context of TS 3R homozygosity.
RESULTS
The analysis of MTHFR genotypes (Table 1) showed that individuals bearing the T677A1298 haplotype were found at a higher frequency in the group of children who experienced an event. Individuals with this haplotype (essentially corresponding to T677 carriers) were at a higher risk of event compared to other MTHFR genotype groups (hazard ratio (HR) ¼ 2.2, 95% confidence interval (CI), 1.0-4.7, P ¼ 0.04). Within our sample, the observed association did not seem to be dependent on the presence or absence of the MTHFR 1298 variant (ie it was not exclusively due to either the C677C1298 or C677A1298 haplotypes). Similarly, KaplanMeier EFS estimates showed that T677A1298A individuals had a lower probability of 5-year post-treatment EFS compared to other genotype groups (P ¼ 0.03, Figure 1a) . Likewise, the MTHFD1 A1958 variant was associated with an increased risk of event (HR ¼ 2.8, 95% CI, 1.1-7.3 P ¼ 0.03), and hence a lower probability of EFS (P ¼ 0.02, Figure 1b) . The inclusion of previously analyzed genotypes that correlated with ALL outcome (see Materials and methods section) in the multivariate model did not affect the results for the MTHFR T677A1298 haplotype or MTHFD1 A1958 variant (respective HRs are 2.1, 95% CI, 1.0-8.4 and 2.5, 95% CI, 1.0-6.4). When patients and disease characteristics (see Materials and methods section) were entered together with MTHFR or MTHFD1 genotype in the Cox regression model, HR estimates for MTHFR T677A1298 did not change the output values of the test (HR ¼ 2.2, 95% CI, 0.9-5.6), although due to the reduced power, the level of significance was lost (P ¼ 0.1). In contrast, risk of event associated with the MTHFD1 A1958 allele was reduced in a multivariate analysis (HR ¼ 1.7, 95% CI, 0.9-4.4, P ¼ 0.3), suggesting that the MTHFD1 variant does not independently affect the probability of event in patients with ALL. Further analysis of DFS (n ¼ 30) showed a similar multivariate HR, as in EFS analysis for both the MTHFR T677A1298 haplotype (HR ¼ 3.3, 95% CI, 1.1-9.9, P ¼ 0.03) and MTHFD1 A1958 variant (HR ¼ 1.6, 95% CI, 0.8-5.8, P ¼ 0.4), whereas no association was found between either of the polymorphisms and OS (n ¼ 19, respective multivariate HRs are 2.0, 95% CI, 0.5-7.4, P ¼ 0.3 and 1.9, 95%, CI 0.4-9.0, P ¼ 0.4). We did not observe a significant difference between individuals with or without the T677A1298 haplotype or MTHFD1 A1958 allele with regard to missed weeks of MTX due to drug toxicity, or average drug dose received weekly. These parameters remained constant when only homozygous individuals were taken into account (ie MTHFR TT677, MTHFR CC1298 or MTHFD1 AA), and compared to individuals without these genotypes.
Following the hypothesis that the conservation of 5,10-methylene-THF, via altered MTHFR or MTHFD1 activity, would facilitate thymidylate synthesis, particularly in individuals with the 3R3R genotype of the TS gene, we studied the association of combined TS and MTHFR, or MTHFD1 event-predisposing genotypes. Individuals with both TS 3R3R and MTHFR T677A1298 or TS 3R3R and MTHFD1 A1958 genotypes had a remarkably lower probability of 5-year post-treatment EFS, compared to subjects with no event-predisposing genotypes (54 vs 93%, P ¼ 0.0001 and 45 vs 95%, P ¼ 0.0002, respectively, Figure  1c and d). Significant association is retained during Cox's regression analysis in the presence of other prognostic factors (respective HRs are 9.0, 95% CI, 1.9-42.8, P ¼ 0.006 and 8.9, 95% CI, 1.8-44.6, P ¼ 0.007), or when applying a correction for multiple testing. The results did not change if DFS was analyzed instead of EFS, whereas no association was found between combined genotypes and OS (data not shown). No correlation between combined genotypes and MTX dosage, or frequency of weeks with MTX dose reduction or withdrawal was observed. And finally, no interaction between the MTHFR and MTHFD1 genotypes was seen (data not shown).
DISCUSSION
MTHFR plays a key role in folate metabolism by channeling one-carbon units between nucleotide synthesis and methylation reactions.
2 Reduced 5 0 methyl-THF levels may decrease homocysteine methylation to methionine, resulting in hyperhomocysteinemia and DNA hypomethylation. 25 On the other hand, reduced levels of 5,10-methylene-THF, required for thymidylate synthesis, could lead to uracil misincorporation into DNA, increasing the frequency of chromosome damage, 25, 26 the effect that facilitates the action of certain chemotherapeutics, including that of MTX. In addition to MTHFR, maintenance of the folate pool is provided by MTHFD1, which plays an important role in the generation of the 5,10-methylene-THF and 10-formyl-THF required for de novo purine and thymidylate synthesis. 3 Since the effect of MTX depends upon intracellular THF depletion, 27 it is quite possible that alterations in the reduced folate pools, influenced by MTHFR and MTHFD1 polymorphisms, may affect MTX sensitivity. Indeed, several recent studies found that variant MTHFR 677T correlates with MTX toxicity. Using lymphoblasts originating from ALL patients who suffered MTX-related toxicity, Taub et al 13 found that those with the TT genotype exhibited greater in vitro MTX sensitivity when compared to patients with other genotypes. 13 MTX toxicity recorded during the maintenance phase of adult ALL treatment was significantly increased in TT677 patients, in whom myelosuppression and liver toxicity seemed particularly pronounced.
14 A similar effect of the MTHFR polymorphisms was also observed for other diseases treated by MTX. For example, MTHFR TT677 patients with CML who received MTX for the prevention of a graft-versus-host disease, experienced higher toxicity, as documented by increased oral mucositis and delayed platelet recovery. 15 Increased MTX toxicity was also noted in ovarian cancer patients with the TT677 genotype, 28 and in patients with rheumatoid arthritis who were carriers of the T677A1298 haplotype. 16 MTX-associated effects observed in these studies were suggested to arise due to low 5-methyl-THF levels associated with the T677 variant.
In our study, we did not observe any association between MTHFR or MTHFD1 polymorphisms and MTX toxicity in childhood ALL patients, at least not to the extent that it would lead to MTX withdrawal or dose reduction. Further analyses beyond the MTX dose are needed to confirm this observation. In contrast, we observed an association between the MTHFR1 T677A1298 haplotype and risk or relapse (ie an association of the MTHFR variant with both EFS and 
DFS, but not OS)
. This observation could be explained by the fact that T677 carriers conserve more 5,10-methylene-THF than carriers of other genotype groups, which would slow the incorporation of uracil into DNA, and might therefore reduce MTX efficacy. Individuals with the C677A1298 or C677C1298 haplotypes appeared protected from the event, suggesting, at least in our study, that the C1298 variant has little influence on ALL outcome. The association of the MTHFR C1298 variant with parameters of MTX sensitivity was less frequently studied than that of T677, and so far has been assessed only in studies of rheumatoid arthritis, among which one study showed that patients with the C677C1298 haplotype responded better to the MTX treatment, 16 while in another study no influence of any of the MTHFR polymorphisms was observed. 29 With regard to the MTHFD1 polymorphism, its functional role in folate pool maintenance has been suggested: women with the MTHFD1 AA1958 genotype were found to be at an increased risk of having NTD-affected offspring. 18 In addition, the conservation of an arginine residue at the corresponding position of the MTHFD1 gene across numerous species suggests that replacement with glutamine, caused by a G to A base substitution, may have functional consequences. 18 Since MTHFD1 arg653gln replacement lies within the 10-formyl-THF synthase domain of MTHFD1, it is possible that a reduction in 10-formyl THF formation could shift folate balance towards 5,10-methylene-THF pools required for TS synthesis. In addition, genomic imbalance corresponding to the MTHFD1 locus was found in MTXresistant T-cell ALL cell lines. 30 The association of both gene polymorphisms, and particularly that of MTHFD1, appears more obvious when combined with other variants within the same pathway. The known mechanism of MTX further supports this observation. MTX-induced depletion of folate cofactors such as 10-formyl-THF and 5-10-methylene-THF contributes to the inhibition of the folate-dependent enzymes of de novo purine and thymidylate synthesis. 31 It was suggested that depletion of these factors alone would not be sufficient to inhibit folate-dependent enzymes. 32, 33 Indeed, several studies confirmed that MTX polyglutamates are potent inhibitors of folate-dependent enzymes, [19] [20] [21] 32 providing evidence that inhibition of de novo thymidylate synthesis consists of both substrate depletion and direct enzymatic inhibition. It can then be speculated that lower levels of TS and 5,10-methylene-THF would facilitate MTX action while, in contrast, high levels would mediate MTX resistance. The latter would be expected for homozygous TS 3R individuals with the MTHFR T677A1298 haplotype or possibly MTHFD1 A1958 variant, thus explaining the highly significant reduction in the relapse rate for individuals with those genotype combinations.
It is also possible that the association observed between polymorphisms analyzed herein and disease outcome arises due to the their impact on malignancy progression, since both the MTHFR T677 and TS 3R variants were found to influence susceptibility to ALL. [34] [35] [36] Higher 5,10-methylene-THF and TS levels associated with these variants were suggested to limit DNA damage by reducing uracil incorporation into DNA, thus explaining the protective role of these variants against leukemia. 35 On the other hand, this might also favor the proliferation of residual malignant clone.
In conclusion, our study provides further evidence of the critical role played by the enzymes of the folate pathways in ALL outcome, possibly through interference with MTX action. The association of the MTHFR T677A1298 haplotype and MTHFD1 A1958 allele with reduced EFS and DFS is particularly obvious when combined with other eventpredisposing variants within the same pathway. Keeping in mind the small sample size of our study, this finding should be replicated in independent and larger patient cohorts. In addition, given the complex mechanism of folate pool maintenance, as well as that of MTX resistance, polygenic effects on ALL outcome and MTX sensitivity are expected beyond the influence of the two loci shown here. The whole range of both cytoplasmatic and mitochondrial enzymes might play a role in the outcome of this disease. For example, the enzymes affecting folate catabolism 37 or methylene-THF synthesis might be of importance. 38, 39 Similarly, the mitochondrial counterpart of MTHFD1, the NAD-dependent methylenetetrahydrofolate dehydrogenase, can influence 10-formyl-THF generation that in turn contributes to the cytoplasmatic folate pools. 40 In order to analyze the whole range of polymorphisms underlying other enzymatic variants within the folate pathway, as well as their possible gene-gene interactions, it is necessary that much larger and more collaborative studies be undertaken, if we are to understand the role of gene polymorphisms in ALL outcome.
MATERIALS AND METHODS

Study Population
The patients (n ¼ 201) included in this study were children with ALL of French-Canadian origin treated at SainteJustine Hospital, Montreal, Canada, between 1988 and 2000, with the multiagent chemotherapeutic protocols DFCI 87-01, 91-01 or 95-01 of the Dana-Farber Cancer Institute. 24 The details of the MTX administration are given elsewhere. 41 Information concerning the reduction and increase of MTX dose carried out according to the protocols was available for 185 patients. Patient samples were obtained at diagnosis after informed consent. The Hospital Ethical Committee approved the study protocol. The distribution of prognostic factors at diagnosis (sex, age, white blood cell (WBC) count, ALL immunophenotype, treatment protocol, risk group and DNA index) among individuals with and without event was as described previously. 41 For analysis, patients were categorized according to relapse risk prediction (boys or girls; age below 1 year, 1-10 and above 10; WBC below or above of 50 Â 10 9 ; B-or Tcell type; standard, high or very high risk and DNA index above or below 1.16, corresponding to 50 chromosomes). 41 Children who relapsed or had a fatal outcome due to the disease were defined to have had an event.
Genotyping Polymorphic MTHFR and MTHFD1 sites were screened by allele-specific oligonucleotide (ASO) hybridization. DNA segments containing the polymorphic sites were amplified by PCR using 15 ng of genomic DNA, 0.5 mM of each of the primers, 100 mM dNTPs, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 50 mM KCl and 0.5 U of Taq polymerase (Platinum, InVitroGene) in a total volume of 50 ml for 35 cycles composed of 30 s at 941C, 30 s at 621C, 51 or 621C (for sites MTHFR 677, MTHFR 1298 and MTHFD1 1958, respectively), and 45 s at 721C. The sequence of forward and reverse primer pairs used for the amplification of the regions encompassing the MTHFR 677, MTHFR 1298 and MTHD1 1958 polymorphisms were: tgaaggagaaggtgtctgcgg and agga cggtgcggtgagagtg, ctttggggagctgaaggacta and cactttgtgaccat tccggttt and cactccagtgtttgtccatg and gcatcttgagagccctgac, respectively.
The resulting PCR products were dot-blotted in duplicate on a nylon membrane and assayed for the presence or absence of one or the other variant by ASO hybridization, as described in Labuda et al. 42 ASO probes specific for the MTHFR C677 (gcgggagCcgatttc), MTHFR T677 (gcgggagTc gatttc), MTHFR A1298 (ccagtgaagAaagtg), MTHFR C1298 (ccagtgaagCaagtg), MTHFD1 G1958 (cagaccGgatcgcac) and MTHFD1 A1958 (cagaccAgatcgcac) alleles were designed and hybridized at 501C (MTHFR 677 and MTHFD1 1958) or 521C (MTHFR 1298). 24, 41, 43 In EFS analysis, survival time corresponded to the time between diagnoses and event (n ¼ 35), whereas for the censored cases it corresponded to time between diagnosis and the end of follow-up (5 years post-treatment) or February 2002 (for patients receiving therapy or those who have entered the follow-up period). In the event group, the survival time ranged from 1 to 84 months with a median of 19 months, and in the nonevent group, it ranged from 12 to 84 months with a median of 60 months. In DFS analysis (n ¼ 30), survival time corresponded to the time between diagnosis and relapse (range 1-84 and median of 26.5 months), while in OS analysis (n ¼ 19) it corresponded to the time between diagnosis and fatal outcome (range 1-84 and median of 20 months).
Statistics
To estimate gene-gene interaction, we performed a stratified analysis. For the analysis of survival probabilities in the function of two genes, individuals for the double TS repeat and having the MTHFD GG genotype or a haplotype other than MTHFR T677A1298, were defined as having a low-risk genotype combination and hence considered as a reference.
The correlation between MTHFR and MTHFD1 genotypes and MTX dosage (mg/m 2 /week), and the frequency of weeks with reduced or missed doses of MTX, were correlated using Spearman's rank-correlation test.
The analyses were carried out using the SPSS statistical package (Version 10.0).
